To understand the situation and drug sensitivity of antenatal group B streptococcus infection in perinatal pregnant women, and to provide basis for the prevention and treatment of group B streptococcus infection in neonates.

From January 2019 to March 2020, a total of 4 750 samples of vaginal secretions from pregnant women at 35~37 weeks of gestation were collected from Suqian Maternity Hospital, Rugao Maternity Hospital and Rugao Guangci Hospital for the isolation and identification of group B streptococcus; The drug sensitivity test of the positive strain was carried out by K-B method.

225 strains of group B streptococcus were detected in 4 750 samples of vaginal secretions, with a detection rate of 4.74%. Among the drug sensitivity results, no strains resistant to penicillin, vancomycin and linezolid were detected, but the sensitivity of penicillin decreased, and the inhibitory zone accounted for 5.33% at the sensitive fold point; The drug resistance rates of chloramphenicol, levofloxacin, clindamycin and erythromycin were 7.61%, 57.94%, 70.98% and 80.44% respectively. The positive rate of induction clindamycin test was 9.43%.

In perinatal period, the infection rate of group B streptococcus vaginal secretions reached 4.74%, and lactams showed no resistance, but the sensitivity of penicillin showed a decline. Clinical attention should be paid to the screening of group B streptococcus in perinatal pregnant women, which should be effectively prevented through prenatal screening and drug sensitivity test, and preventive treatment should be done to reduce the rate of maternal and infant patients.